💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tacrine

CHEMBL95 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
198.3 g/mol
LogP
2.7
Phase
4

Tacrine (tetrahydroaminoacridine, THA) is a first-generation reversible acetylcholinesterase inhibitor used historically for symptomatic treatment of mild-to-moderate Alzheimer's disease, acting by inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase to increase acetylcholine levels in cholinergic synapses in the cortex and hippocampus. It also has additional activities including NMDA receptor antagonism, potassium channel blockade, and monoamine oxidase inhibition. Due to high hepatotoxicity risk and the availability of better-tolerated cholinesterase inhibitors, it has been largely discontinued.

Molekularmasse

198,2600 g/mol

LogP

2,70

TPSA

38,90 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Cardiovascular Disease Respiratory Disease Ophthalmology Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Hyperlipidemia Type 2 Diabetes

Wirkmechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Nc1c2c(nc3ccccc13)CCCC2

                

                

                
                

                    
InChI

                    
InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)

                

                

                

                    
                    

                        
Molecular Formula

                        
C13H14N2

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
Rotierbare Bindungen

                        
0

                    

                    
                    
                    

                        
Schwere Atome

                        
15

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
Tacrine (tetrahydroaminoacridine, THA) is a first-generation reversible acetylcholinesterase inhibitor used historically for symptomatic treatment of mild-to-moderate Alzheimer's disease, acting by inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase to increase acetylcholine levels in cholinergic synapses in the cortex and hippocampus. It also has additional activities including NMDA receptor antagonism, potassium channel blockade, and monoamine oxidase inhibition. Due to high hepatotoxicity risk and the availability of better-tolerated cholinesterase inhibitors, it has been largely discontinued.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tacrine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL95.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 1935.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.